Denali Therapeutics Inc (NASDAQ:DNLI) price on Friday, November 15, fall -11.95% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $25.05.
A look at the stock’s price movement, the close in the last trading session was $28.45, moving within a range at $24.995 and $28.45. The beta value (5-Year monthly) was 1.394. Turning to its 52-week performance, $33.33 and $14.56 were the 52-week high and 52-week low respectively. Overall, DNLI moved -8.64% over the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Denali Therapeutics Inc’s market cap currently stands at around $3.61 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-25.
Wall Street analysts have also projected the company’s year-on-year revenue to grow to 13.15M, representing a -96.02% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that DNLI is a Hold. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 4 recommend DNLI as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
DNLI’s current price about -9.96% and -11.16% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 37.93, while 7-day volatility ratio is 7.53% and 5.15% in the 30-day chart. Further, Denali Therapeutics Inc (DNLI) has a beta value of 1.39, and an average true range (ATR) of 1.61. Analysts have given the company’s stock an average 52-week price target of $35, forecast between a low of $22 and high of $70. Looking at the price targets, the low is 12.18% off current price level while to achieve the yearly target high, price needs to move -179.44%. Nonetheless, investors will most likely welcome a -39.72% jump to $35 which is the analysts’ median price.
If we refocus on Denali Therapeutics Inc (NASDAQ:DNLI), historical trading data shows that trading volumes averaged 0.88 over the past 10 days and 842.27K over the past 3 months. The company’s latest data on shares outstanding shows there are 138.39 million shares.
The 13.46% of Denali Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 88.39% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 7.43 million on 2024-10-31, giving us a short ratio of 11.35. The data shows that as of 2024-10-31 short interest in Denali Therapeutics Inc (DNLI) stood at 603.99998 of shares outstanding, with shares short falling to 7.74 million registered in 2024-09-30. Current price change has pushed the stock 16.73% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the DNLI stock continues to rise going into the next quarter.
